Antifungal drug development: challenges, unmet clinical needs, and new approaches.
about
Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Sphingolipids as Regulators of the Phagocytic Response to Fungal InfectionsSystem-level impact of mitochondria on fungal virulence: to metabolism and beyondCopper at the Fungal Pathogen-Host AxisNew insights into TB physiology suggest untapped therapeutic opportunitiesThe Repurposing of Anti-Psychotic Drugs, Quetiapine and Olanzapine, as Anti-Cryptococcus DrugsAntitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase.The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.Plasma Membrane Proteolipid 3 Protein Modulates Amphotericin B Resistance through Sphingolipid Biosynthetic Pathway.Rising to the challenge of multiple Cryptococcus species and the diseases they cause.A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance.Noncanoncial signal recognition particle RNAs in a major eukaryotic phylum revealed by purification of SRP from the human pathogen Cryptococcus neoformansBypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1.Integrated Activity and Genetic Profiling of Secreted Peptidases in Cryptococcus neoformans Reveals an Aspartyl Peptidase Required for Low pH Survival and Virulence.High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance.Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis.Collaborative Total Synthesis: Routes to (±)-Hippolachnin A Enabled by Quadricyclane Cycloaddition and Late-Stage C-H OxidationEditorial: Antifungal Drug Discovery: New Theories and New TherapiesF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.Blad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell.Candida antifungal drug resistance in sub-Saharan African populations: A systematic review.Combinatorial strategies for combating invasive fungal infections.In silico screening for identification of novel β-1,3-glucan synthase inhibitors using pharmacophore and 3D-QSAR methodologies.Development of antifungal therapies using nanomaterials.Antifungals: Mechanism of Action and Drug Resistance.Co-culturing of Fungal Strains Against Botrytis cinerea as a Model for the Induction of Chemical Diversity and Therapeutic AgentsNewer patents in antimycotic therapy.New facets of antifungal therapy.The GPI anchor pathway: a promising antifungal target?Sphingolipids as targets for treatment of fungal infectionsStrategies in the discovery of novel antifungal scaffolds.Immunoproteomics of Aspergillus for the development of biomarkers and immunotherapies.Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development.The anti-Aspergillus drug pipeline: Is the glass half full or empty?Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans.Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.High-Throughput Screen in Cryptococcus neoformans Identifies a Novel Molecular Scaffold That Inhibits Cell Wall Integrity Pathway Signaling.A Cationic Polymer That Shows High Antifungal Activity against Diverse Human Pathogens.Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida.Mitochondrial Cochaperone Mge1 Is Involved in Regulating Susceptibility to Fluconazole in Saccharomyces cerevisiae and Candida Species.
P2860
Q26740363-96C64C2F-372E-493D-A983-657D0B8F7025Q26774635-F436B65D-D39D-4F28-8C04-5C946F3936C8Q26996390-02684291-E8B3-4C23-BD2D-97E43B81BFA9Q27010264-F09D23CA-EACB-425B-A7B3-0B702E5B138EQ28388477-99E9A734-15DA-464F-B3C4-50763221CD97Q33650197-12F87B24-BF74-4641-8347-87C08AA47F7CQ34522517-30CAD058-1C18-4FEF-8B4A-7460F07AD9ECQ34540684-979CAB5B-F6EB-4376-A688-BA804544E824Q35596158-82441D87-ECAF-4CF7-8930-1FE8C468A10FQ35706177-04B4845C-DCE9-42AD-93B1-9B1C85148AE9Q35874892-03ABEB6A-4C46-4A7E-B8CA-629DDFB4C133Q36160650-25508F55-ACF7-4A68-98D3-C9280AB066B9Q36217628-FF87919A-1BF5-4961-8D68-D5776099795AQ36225321-42F328D9-505E-451D-BCC2-F2D21D3B9DBDQ36410455-12FA469E-3E19-4E01-9296-1DEEBEC4D172Q36539252-6EDFA5F2-9D91-446F-AA53-0B0866A402B5Q36900206-4BF301C1-4928-49EF-8588-8A3DDC3B7CA1Q36925961-23E78780-2D64-49BC-95AA-9BFBF0F85773Q37417882-53EBA7C4-F23B-4FE1-8FCC-B9BADA648E3EQ37438608-156BEB93-3FBB-4C51-8588-DE6F1C999C4AQ37595435-8DE88221-33B9-4E51-84FC-FE7722B117CEQ37705303-0F05C438-8E63-4800-91B6-3B18ACFC6844Q38378762-C0728551-08A2-4803-B467-F5D594AF9880Q38658275-BEC9BBFA-786F-4C03-84EE-C04C61062228Q38684281-35BF285F-D9CF-4ADC-B440-2D1D16A460E6Q38704964-5157E727-AA9A-49C5-8511-CC2BE1D7D567Q38743672-359F8A72-E89C-46BC-9682-64606A638113Q38797864-57E8A206-45B2-42A0-A09A-51B13ECECF68Q38832565-066BB7E8-BD59-425E-9D5E-3A9429D0F8ECQ38833311-EBFA04A8-9B2D-4000-92B3-8781ADD3DC4EQ38837363-7875664F-EBE4-49EC-B93F-8FB9973B76E0Q38867587-AF0C6260-4019-43B6-B84D-6C7DEC2DDF27Q38905119-B52DA20C-5901-4C3D-8833-B23E8D35E354Q38937577-E5AFEE52-CE83-4A4F-8099-FBAD3F7FA00EQ38975472-D85A2808-6D0C-4A9F-9F1C-DC9F1360CAA9Q39338332-7D2019BA-3032-4E49-BF99-7DD1046AAD18Q40065529-C7FA9C91-8E18-4153-956D-2B3EFC546181Q40121770-EED987D8-9391-41DD-8CE0-55693015AD0CQ40129238-C1B53595-9F20-4AB9-9074-308C0EB06BFFQ40129343-4FFD95D3-B75C-436C-B8DA-9D8148A8FC13
P2860
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@en
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@nl
type
label
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@en
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@nl
prefLabel
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@en
Antifungal drug development: challenges, unmet clinical needs, and new approaches.
@nl
P2860
P1476
Antifungal drug development: challenges, unmet clinical needs, and new approaches
@en
P2093
Terry Roemer
P2860
P356
10.1101/CSHPERSPECT.A019703
P577
2014-05-01T00:00:00Z